drugset / Trial / NCT00346957
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
Timeline
- Start
- 1999-04
- Primary completion
- 2003-04
- Completion
- 2003-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Small molecule | 3 mg | Other |
| Subject | Anecortave Acetate | Small molecule | 15 mg | Other |
| Subject | Anecortave Acetate | Small molecule | 30 mg | Other |
Indications
No indication recorded.